Healthcare provider profile · identity verified

Bikash Agarwal, MD

Allopathic & Osteopathic Physicians|Internal Medicine · MICHIGAN CITY, IN · NPI 1093700825

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Bikash Agarwal, MD received $250.00 in general payments during 2025 across 2 reported records.

ANI Pharmaceuticals, Inc. accounted for 50.0% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 2 associated products.

A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.

Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 175 claims for Jardiance by this doctor in 2024.

Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Mounjaro by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$250.00

2 reported records · 2 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
ANI Pharmaceuticals, Inc.	Unresolved — no canonical attribution shown	$125.00	50.0%	1	2025
Lilly USA, LLC	Unresolved — no canonical attribution shown	$125.00	50.0%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$250.00	2

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
JARDIANCE Normalized: jardiance	Drug	Lilly USA, LLC	$125.00	1	2025
Source payment records 2025-02-22 · Lilly USA, LLC · $125.00 · Open Payments source
PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel	Drug	ANI Pharmaceuticals, Inc.	$125.00	1	2025
Source payment records 2025-09-19 · ANI Pharmaceuticals, Inc. · $125.00 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments product	Payment year	Part D brand	Part D year	Claims	Match method	Source
JARDIANCE jardiance	2025	Jardiance	2024	175	exact normalized	Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
Lilly USA, LLC Exact reporting entity; no affiliate inference	2025	JARDIANCE open payments reported associated product	CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557	Jardiance · 2024 Exact normalized brand match · 1 Part D row	175	43
Lilly USA, LLC Exact reporting entity; no affiliate inference	2025	MOUNJARO open payments reported associated product	CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455	Mounjaro · 2024 Exact normalized brand match · 1 Part D row	15	suppressed by CMS

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	1030	201
Levothyroxine Sodium	Levothyroxine Sodium	654	131
Amlodipine Besylate	Amlodipine Besylate	522	104
Carvedilol	Carvedilol	520	109
Furosemide	Furosemide	479	88
Losartan Potassium	Losartan Potassium	450	94
Pantoprazole Sodium	Pantoprazole Sodium	432	83
Tamsulosin Hcl	Tamsulosin Hcl	410	69
Eliquis	Apixaban	389	53
Lisinopril	Lisinopril	378	82
Metoprolol Tartrate	Metoprolol Tartrate	366	49
Sertraline Hcl	Sertraline Hcl	293	45
Clopidogrel	Clopidogrel Bisulfate	276	47
Gabapentin	Gabapentin	261	37
Metformin Hcl	Metformin Hcl	258	57
Memantine Hcl	Memantine Hcl	243	25
Hydrochlorothiazide	Hydrochlorothiazide	222	44
Donepezil Hcl	Donepezil Hcl	221	32
Omeprazole	Omeprazole	217	35
Rosuvastatin Calcium	Rosuvastatin Calcium	206	39
Spironolactone	Spironolactone	177	57
Jardiance	Empagliflozin	175	43
Potassium Chloride	Potassium Chloride	168	29
Mirtazapine	Mirtazapine	158	26
Metoprolol Succinate	Metoprolol Succinate	153	56
Famotidine	Famotidine	146	50
Prednisone	Prednisone	128	47
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	125	42
Lamotrigine	Lamotrigine	106	suppressed
Myrbetriq	Mirabegron	104	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	102	55
Montelukast Sodium	Montelukast Sodium	98	15
Duloxetine Hcl	Duloxetine Hcl	96	18
Allopurinol	Allopurinol	93	24
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	90	14
Trazodone Hcl	Trazodone Hcl	89	22
Warfarin Sodium	Warfarin Sodium	87	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	86	suppressed
Simvastatin	Simvastatin	83	25
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	78	25
Entresto	Sacubitril/Valsartan	77	suppressed
Finasteride	Finasteride	74	17
Tacrolimus	Tacrolimus	70	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	69	13
Fluvoxamine Maleate	Fluvoxamine Maleate	68	suppressed
Fluticasone Propionate	Fluticasone Propionate	62	32
Doxycycline Hyclate	Doxycycline Hyclate	61	50
Cephalexin	Cephalexin	60	47
Divalproex Sodium	Divalproex Sodium	59	suppressed
Xifaxan	Rifaximin	58	suppressed
Hydroxychloroquine Sulfate	Hydroxychloroquine Sulfate	56	suppressed
Anastrozole	Anastrozole	53	suppressed
Galantamine Hbr	Galantamine Hbr	53	suppressed
Latanoprost	Latanoprost	52	12
Pravastatin Sodium	Pravastatin Sodium	50	12
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	50	15
Xarelto	Rivaroxaban	48	12
Breo Ellipta	Fluticasone/Vilanterol	47	suppressed
Bupropion Hcl Sr	Bupropion Hcl	47	suppressed
Ezetimibe	Ezetimibe	47	15
Autoshield Duo Pen Needle	Pen Needle,dual Safety,diabetc	43	14
Bupropion Xl	Bupropion Hcl	43	suppressed
Rivastigmine	Rivastigmine Tartrate	43	suppressed
Metformin Hcl Er	Metformin Hcl	42	12
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	41	37
Gemtesa	Vibegron	41	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	41	suppressed
Nystatin	Nystatin	40	23
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	39	11
Januvia	Sitagliptin Phosphate	38	11
Synthroid	Levothyroxine Sodium	38	suppressed
Levetiracetam	Levetiracetam	37	suppressed
Terazosin Hcl	Terazosin Hcl	37	suppressed
Buspirone Hcl	Buspirone Hcl	36	suppressed
Mycophenolate Mofetil	Mycophenolate Mofetil	35	suppressed
Lactulose	Lactulose	34	13
Lantus	Insulin Glargine,hum.Rec.Anlog	34	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	33	14
Insulin Lispro Kwikpen U-100	Insulin Lispro	33	17
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	31	17
Enulose	Lactulose	31	suppressed
Novolog Flexpen	Insulin Aspart	31	suppressed
Citalopram Hbr	Citalopram Hydrobromide	30	suppressed
Ozempic	Semaglutide	30	11
Atenolol	Atenolol	29	suppressed
Midodrine Hcl	Midodrine Hcl	29	suppressed
Roflumilast	Roflumilast	29	suppressed
Glimepiride	Glimepiride	28	suppressed
Hydralazine Hcl	Hydralazine Hcl	28	11
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	28	17
Ipratropium-Albuterol	Ipratropium/Albuterol Sulfate	27	11
Ondansetron Hcl	Ondansetron Hcl	25	18
Fluoxetine Hcl	Fluoxetine Hcl	24	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	23	suppressed
Solifenacin Succinate	Solifenacin Succinate	21	suppressed
Raloxifene Hcl	Raloxifene Hcl	20	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	19	suppressed
Mupirocin	Mupirocin	19	suppressed
Nebivolol Hcl	Nebivolol Hcl	19	suppressed
Ondansetron Odt	Ondansetron	19	19
Meloxicam	Meloxicam	18	suppressed
Valsartan	Valsartan	18	suppressed
Baclofen	Baclofen	17	suppressed
Cefdinir	Cefdinir	17	13
Cefuroxime	Cefuroxime Axetil	17	14
Fenofibrate	Fenofibrate	17	suppressed
Folic Acid	Folic Acid	17	suppressed
Glipizide	Glipizide	17	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	17	17
Nitroglycerin	Nitroglycerin	17	12
Torsemide	Torsemide	17	suppressed
Benazepril Hcl	Benazepril Hcl	16	suppressed
Propranolol Hcl Er	Propranolol Hcl	16	suppressed
Tresiba Flextouch U-100	Insulin Degludec	16	suppressed
Verquvo	Vericiguat	16	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	15	suppressed
Enalapril Maleate	Enalapril Maleate	15	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	15	suppressed
Hydrocortisone	Hydrocortisone	15	suppressed
Mounjaro	Tirzepatide	15	suppressed
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	15	suppressed
Diclofenac Sodium	Diclofenac Sodium	14	suppressed
Irbesartan	Irbesartan	14	suppressed
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	14	suppressed
Ropinirole Hcl	Ropinirole Hcl	14	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	14	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	14	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	13	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	13	13
Desvenlafaxine Succinate Er	Desvenlafaxine Succinate	13	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	13	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	13	suppressed
Brilinta	Ticagrelor	12	suppressed
Colesevelam Hcl	Colesevelam Hcl	12	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	12	suppressed
Oxcarbazepine	Oxcarbazepine	12	suppressed
Primidone	Primidone	12	suppressed
Sotalol	Sotalol Hcl	12	suppressed
Ultra-Fine Nano Pen Needle	Pen Needle, Diabetic	12	suppressed
Vancomycin Hcl	Vancomycin Hcl	12	suppressed
Zonisamide	Zonisamide	12	suppressed
Abrysvo	Rsv Vacc, Pref A And Pref B/Pf	11	11
Celecoxib	Celecoxib	11	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	11	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	11	11
Ramipril	Ramipril	11	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$250.00 · 2 records	ANI Pharmaceuticals, Inc.	JARDIANCE, PURIFIED CORTROPHIN GEL	2	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

What role, if any, does Jardiance play in your treatment recommendations for me?
How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error